Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.05B 3.51B 3.32B 3.01B 5.65B 389B 5.68B 39.64B 15.32B 197B 15.23B 14.89B 629B P/E 2026 *
9.23x
P/E 2027 * 8.37x
Enterprise Value 4.04B 3.5B 3.31B 3.01B 5.63B 388B 5.67B 39.52B 15.27B 197B 15.18B 14.84B 627B EV / Sales 2026 *
3.03x
EV / Sales 2027 * 2.49x
Free-Float
98.18%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 4.04B
+0.15%+1.21%+48.79%+97.65% 1,013B
+0.03%+0.07%+51.47%+65.55% 644B
-0.20%+4.62%+21.39%+72.57% 465B
+0.53%+4.26%+40.29%+38.70% 352B
+0.39%+2.35%+17.96%+23.87% 264B
+0.17%+4.17%+6.96%+10.93% 253B
+0.19%-3.81%+37.81%+44.35% 203B
-1.20%-5.64%-24.09%-59.10% 188B
+0.94%+1.39%+33.21%+95.16% 181B
Average +0.11%-0.62%+28.33%+36.95% 395.97B
Weighted average by Cap. +0.11%+0.32%+34.35%+59.58%

Financials

2026 *2027 *
Net sales 1.33B 1.15B 1.09B 990M 1.86B 128B 1.87B 13.02B 5.03B 64.81B 5B 4.89B 207B 1.4B 1.21B 1.15B 1.04B 1.95B 134B 1.96B 13.68B 5.29B 68.1B 5.26B 5.14B 217B
Net income 474M 411M 388M 353M 661M 45.5B 665M 4.64B 1.79B 23.08B 1.78B 1.74B 73.56B 530M 459M 434M 394M 739M 50.84B 743M 5.18B 2B 25.79B 1.99B 1.95B 82.19B
Net Debt -12.5M -10.83M -10.24M -9.3M -17.42M -1.2B -17.52M -122M -47.23M -608M -46.96M -45.91M -1.94B -570M -494M -467M -424M -794M -54.68B -799M -5.57B -2.15B -27.73B -2.14B -2.09B -88.4B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
34.35USD
Average target price
49.00USD
Spread / Average Target
+42.65%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!